This Best Practices Report intends to bring our experience in European Industrial Doctorates (EID) to other consortia with awarded EID Programmes ongoing and to institutions considering applying for funding to this scheme.
Tuberculosis and antimycobacterial drug disovery
Despite the existence of treatments, tuberculosis is a painful reality for the nearly nine million people infected, and the one and a half million that die, each year. The disease is also an escalating threat for global health, with the increasing prevalence of Multi Drug Resistant (MDR) TB strains and Extremely Drug Resistant (XDR) TB strains. In some East Europe and Central Asia Countries, MDR/XDR strains account for up to 22 % of infections, with mortality rates for XDR reaching up to 100 % of those infected.
The reasons behind the lack of new medicines for the treatment of TB over the last 40 years are mainly related to a lack of critical mass, both in terms of funding and commercial interest as well as attracting the best minds to address one of the most pressing medical emergencies of the planet.
Attracting and training a new generation of Medicinal Chemists in an Industry/Academia open innovation environment for antimycobacterial drug discovery by offering a set of unique complementary training benefits for young scientists.
Our researchers will carry out PhD research during consecutive training phases in academia (University of Antwerp, Belgium) and Industry (GSK I+D, Spain).
OpenMedChem's Scientific Objectives
- Medicinal chemistry at the helm: To synthesise and evaluate the antitubercular activity of novel analogues of hit compounds identified in a GSK corporate HTS antimycobacterial campaign (>2 million compounds) through a combination of systematic and innovative synthesis and chemo-informatics strategies.
- To characterise antimycobacterial behaviour of prepared compounds via a combination of standard assays (MIC), novel assays (cidality, intracellular activity) and innovative single cell imaging-based approaches.